TL;DR: Aetna, a CVS Health company, confirmed CPB 0706 classifies anecortave acetate (Retaane) as experimental, investigational, or unproven for all current indications — effective November 26, 2025. Any claim you submit with ICD-10 codes for age-related macular degeneration, glaucoma, or retinoblastoma tied to this drug will be denied.
If your ophthalmology or oncology billing team is still testing coverage for anecortave acetate, stop. The Aetna anecortave acetate coverage policy leaves no room for interpretation. CPB 0706 in the Aetna system covers three diagnosis categories — AMD, glaucoma, and retinoblastoma — and rejects coverage for all three. There are no approved indications. There is no path to reimbursement under this policy.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Anecortave Acetate (Retaane) — CPB 0706 |
| Policy Code | CPB 0706 |
| Change Type | Modified |
| Effective Date | November 26, 2025 |
| Impact Level | Medium — any active billing for this drug needs to stop |
| Specialties Affected | Ophthalmology, Pediatric Oncology, Retina Specialists |
| Key Action | Flag and suppress any claims for anecortave acetate billed to Aetna under ICD-10 codes H35.31–H35.32, H40.001–H42, or C69.20–C69.22 |
Aetna Anecortave Acetate Coverage Criteria and Medical Necessity Requirements 2025
Here is the short version: there are none. Aetna does not cover anecortave acetate for any indication. The coverage policy under CPB 0706 designates this drug as experimental, investigational, or unproven across every clinical use case the policy addresses.
That means medical necessity is never met for anecortave acetate under this policy. You cannot document your way around it. There are no clinical criteria to satisfy, no prior authorization pathway that unlocks coverage, and no exceptions for compassionate use or clinical trial participation listed in this bulletin.
The Aetna anecortave acetate coverage policy is a blanket exclusion. If a provider orders Retaane and your team bills it to Aetna, you are looking at a claim denial — not a documentation fix.
Understanding the scope matters here. The policy explicitly states the list of excluded indications is "not all-inclusive." That language is a signal. Aetna is not saying only AMD, glaucoma, and retinoblastoma are excluded. They are saying those are the examples they chose to document. Any new indication a provider might argue for faces the same experimental designation until Aetna's clinical policy unit publishes a specific coverage determination saying otherwise.
This is not a prior authorization situation where the right documentation gets you paid. This is a categorical denial policy. Treat it that way.
Aetna Anecortave Acetate Exclusions and Non-Covered Indications
CPB 0706 lists three specific indications as experimental, investigational, or unproven. All three are flat denials.
Age-Related Macular Degeneration (AMD) — This is the indication anecortave acetate was originally developed to treat. Retaane was studied as an angiostatic steroid to slow choroidal neovascularization. It never cleared the bar for clinical effectiveness. Aetna's position has been consistent: no coverage for AMD. ICD-10 codes H35.3110 through H35.3293 map to this indication.
Glaucoma — The investigational use here involves anecortave acetate's potential to lower intraocular pressure. Aetna considers this unproven. ICD-10 codes H40.001 through H42 cover the glaucoma range affected by this policy.
Retinoblastoma — This is the most clinically serious of the three. Retinoblastoma is a pediatric malignancy, and any investigational treatment option matters to families and providers. But Aetna's coverage policy does not carve out an exception for pediatric cancer. ICD-10 codes C69.20, C69.21, and C69.22 cover malignant neoplasm of the retina under this policy.
The real issue here is the retinoblastoma designation. A pediatric oncology team arguing medical necessity for a child with retinoblastoma will still hit a wall under this policy. If your practice treats retinoblastoma patients who are Aetna members, talk to your compliance officer before assuming any path to reimbursement exists.
Coverage Indications at a Glance
| Indication | Status | Relevant ICD-10 Codes | Notes |
|---|---|---|---|
| Age-Related Macular Degeneration | Not Covered — Experimental | H35.3110–H35.3293 | No prior authorization pathway; blanket denial |
| Glaucoma | Not Covered — Experimental | H40.001–H42 | Includes all glaucoma subtypes in the code range |
| Retinoblastoma | Not Covered — Experimental | C69.20, C69.21, C69.22 | Applies to pediatric oncology cases; no compassionate-use carve-out listed |
| Any other indication | Not Covered — Experimental | Not specified | Policy explicitly notes the exclusion list is not all-inclusive |
Aetna Anecortave Acetate Billing Guidelines and Action Items 2025
These steps are based directly on CPB 0706 as modified effective November 26, 2025.
| # | Action Item |
|---|---|
| 1 | Audit your active claims now. Pull any open or pending claims billed to Aetna that involve anecortave acetate or Retaane. Cross-reference against ICD-10 codes C69.20, C69.21, C69.22, H35.3110–H35.3293, and H40.001–H42. Every one of those is a claim denial waiting to happen. |
| 2 | Update your charge capture to flag this drug. Add anecortave acetate and Retaane to your charge capture system's denial-risk or exclusion flags for Aetna members. Your billing team should see a warning before any claim goes out the door. |
| 3 | Brief your ophthalmology and pediatric oncology providers directly. Providers sometimes submit orders assuming billing will find a path to coverage. There is no path here. Tell your retina specialists and any oncology team treating retinoblastoma patients that Aetna anecortave acetate billing guidelines leave no covered scenario. |
| 4 | Do not attempt prior authorization as a workaround. Some billing teams reflexively try prior auth when they hit a denial. CPB 0706 is not a prior authorization policy — it is an experimental designation. Prior auth won't change the outcome. Save the time. |
| 5 | Check related Aetna policies if the underlying condition needs a covered alternative. Aetna's CPB 0701 covers vascular endothelial growth factor (VEGF) inhibitors for ocular indications — which includes AMD treatment. CPB 0594 covers Visudyne (verteporfin) photodynamic therapy. If a provider is treating AMD or a retinal condition, those policies may offer a reimbursable path. Anecortave acetate billing under this policy does not. |
| 6 | Document patient financial counseling if the provider plans to proceed anyway. If a provider intends to use anecortave acetate off-label and the patient is an Aetna member, your team needs to ensure the patient understands Aetna will not pay. Get an Advanced Beneficiary Notice equivalent or payer-specific waiver signed before treatment. This protects your practice from writing off the cost after the fact. |
| 7 | If you handle appeals, know this one is a policy wall — not a documentation gap. An appeal arguing medical necessity for anecortave acetate under Aetna CPB 0706 requires clinical evidence that effectiveness has been established. That evidence does not currently exist to Aetna's satisfaction. Unless you have new peer-reviewed data that contradicts Aetna's clinical review, an appeal is unlikely to succeed. Talk to your billing consultant before investing time in one. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Anecortave Acetate Under CPB 0706
CPB 0706 does not list specific CPT or HCPCS billing codes for anecortave acetate. This is not unusual for a drug that carries an experimental designation — Aetna's policy defines the exclusion by indication rather than by procedure code.
What the policy does provide is the full set of ICD-10-CM diagnosis codes that define the scope of the exclusion. Any claim pairing anecortave acetate administration with these codes will trigger the experimental/unproven denial.
Key ICD-10-CM Diagnosis Codes Under CPB 0706
| Code | Description |
|---|---|
| C69.20 | Malignant neoplasm of retina, unspecified eye (retinoblastoma) |
| C69.21 | Malignant neoplasm of right retina (retinoblastoma) |
| C69.22 | Malignant neoplasm of left retina (retinoblastoma) |
| H35.3110–H35.3293 | Age-related macular degeneration (range) |
| H40.001–H42 | Glaucoma (range) |
Related Aetna Policy Cross-References
These related coverage policies may be relevant if your team is looking for covered alternatives to anecortave acetate for the same patient population.
| CPB Code | Policy Title | Relevance |
|---|---|---|
| CPB 0701 | VEGF Inhibitors for Ocular Indications | Covered AMD treatment alternative |
| CPB 0594 | Visudyne (Verteporfin) Photodynamic Therapy | Covered AMD treatment alternative |
| CPB 0609 | Laser Photocoagulation of Drusen | Covered AMD-related procedure |
| CPB 0409 | Macular/Foveal Translocation | Related retinal procedure coverage |
If your retina billing team is managing AMD or retinal disease claims for Aetna members, those four policies are your map to what actually gets paid. Anecortave acetate billing does not fit in that map.
A Note on the Effective Date and What "Modified" Actually Means Here
The effective date of November 26, 2025, marks this as a modified policy — not a new one. Anecortave acetate has carried experimental status with Aetna for years. The modification likely reflects updated clinical language, terminology, or a review cycle rather than a coverage position reversal.
That matters for your team because it tells you Aetna is not signaling any openness to covering this drug. A modification to an experimental policy is not a step toward coverage. It is a maintenance update that keeps the denial position current.
If you were watching this policy hoping for a coverage expansion, this update is not that.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.